Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Cancer Vaccines and Peptides

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3167
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Cancer Vaccines and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Cancer Vaccines and Peptides.

    To find out more about Triple Analysis: Leukemia, Cancer Vaccines and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Cancer Vaccines and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
3M Pharmaceuticals
4SC
7TM Pharma
Abbott
Abiogen
AC Immune
Acceleron Pharma
Actinium Pharmaceuticals
Adaptimmune
Advaxis
AEgera
AEterna Zentaris
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alexion
Alfa Wassermann
Allostera
Allosterix
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisoma
Anza Therapeutics
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Arca biopharma
Ardana
Argos Therapeutics
Ariad
Arno Therapeutics
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Bio-Path Holdings
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biokine Therapeutics
BioNTech
BioSante
Biostar
Bioton
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Center of Molecular Immunology
Cephalon
CG Therapeutics
Chemokine Therapeutics
Chiasma
Choongwae
CJ Corp
Clavis Pharma
Cleveland BioLabs
Clinuvel
Compugen
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CreaGene
CSL
Curacyte
Curaxis
CureTech
CureVac
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Digna Biotech
Dong-A
Dongkook Pharm
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Etubics
Exelixis
ExonHit Therapeutics
Formula Pharmaceuticals
Galena Biopharma
Gemin X Biotechnologies
Genencor
Genentech
Generex
Genmab
GenOdyssee Pharmaceuticals
GENova Biotherapeutics
Genovax
Genta
Genticel
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlobeImmune
GlycoGenesys
GlycoMimetics
GP Pharm
Gradalis
Gryphon Therapeutics
Hanmi
Hayashibara
Heat Biologics
Heber Biotec
Hemispherx Biopharma
Hoffmann-La Roche
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
IkerChem
ImClone Systems
immatics biotechnologies
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Incyte Corporation
InDex Pharmaceuticals
Inex
Innate Pharma
Innovive
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KaloBios
Kanisa
Karyon-CTT
Kinex
Kirax
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Memgen
Menarini
Merck & Co
Merck KGaA
MethylGene
Micromet
MolMed
Mologen
Momotaro-Gene
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novartis
NovaRx
Novogen
NPS Pharmaceuticals
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaForm
PharmaGap
PharmaMar
Pharmexa
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Prochon Biotech
Progenics Pharmaceuticals
ProMetic Life Sciences
Protagonist
Protherics
Q Chip
QLT
Radient Pharmaceuticals
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Reliance Life Sciences
responsif
Rigel
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Sepal Pharma
Serometrix
Servier
Shenogen
Shionogi
Shire
Sidus
Soligenix
Southern Research Institute
Spectrum Pharmaceuticals
Spirogen
Stemline Therapeutics
SuperGen
Swedish Orphan Biovitrum
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Tactic Pharma
Takeda
Talon Therapeutics
TapImmune
Targa Therapeutics
TargeGen
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
TopoTarget
Transgene
Trion Pharma
Unigene
United Biomedical
Vaccinex
Valeant
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
Vectura
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest Pharmaceuticals
Viragen
Virionics
ViroMed
XBiotech
Xencor
Xigen
Yamasa Corporation
Zelos Therapeutics
Zensun
Zenyaku Kogyo
Zydus Cadila
A Shortlist of Drugs Included are:
A6
abagovomab
abarelix
ABT-510
ADXS11-001
AE-37
AEZS-108
afamelanotide
AGS-003
alemtuzumab
amonafide malate
amsacrine
angiopep+paclitaxel
ANZ-207
astuprotimut-r
Auto TAG vaccine
AVX-701
barasertib
belagenpumatucel-L
belinostat
bisantrene
bosutinib
BP-GMAX-CD1
BV-NSCLC-001
CB-10-01
CBP-501
CDX-1307
CG-201
cladribine
clofarabine
corticorelin acetate
CreaVax-PC
CSF-GM
CV-9103
CV-9201
CVac
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
DCVax-prostate
decitabine
deslorelin
E-75
elacytarabine
emepepimut-S
enocitabine
EP-100
FPI-01
gemtuzumab ozogamicin
GI-4000
goserelin
GSK-2130579A
GV-1001
GVAX
GVX-3322
GX-301
Her-2/Neu peptides
Hi-8 MEL
histamine dihydrochloride
histrelin
HS-110
ICT-107
idarubicin
imatinib mesilate
imMucin
IMO-2055
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alpha-2b
interleukin-12
IPP-204106
ISA-P53-01
JX-594
kahalalide F
lanreotide
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
lumiliximab
MDX-1379
MGN-1601
midostaurin
mitoxantrone
MVA-BN Her-2 vaccine
NAFB001
netupitant
nilotinib
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ofatumumab
ON-01910
OncoVAX
Onyvax-105
OTS-102
ozarelix
p.DOM-WT1-37/p.DOM-WT1-126 DNA
pasireotide
pasireotide LAR
peginterferon alfa-2b
pentostatin
plitidepsin
poly-ICLC
polyclonal antibody stimulator
PROSTVAC
PSMA ADC
razoxane
Reximmune-C
rhIFN-alpha
rindopepimut
rintatolimod
rituximab
romurtide
S-488410
SCIB-1
sipuleucel-T
sobuzoxane
sotatercept
Survivac
tamibarotene
teniposide
TG-4010
thymalfasin
tipapkinogene sovacivec
tipifarnib
TM-30339
TroVax
vapreotide, immediate-release
velimogene aliplasmid
verpasep caltespen
vitespen
vosaroxin
VX-001
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Cancer Vaccines and Peptides.
    To find out more about Triple Analysis: Leukemia, Cancer Vaccines and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Cancer Vaccines and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Melanoma, Cancer Vaccines and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors. Learn More


Triple Analysis: Apoptosis, Cancer Vaccines and Peptides
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines and by the compound strategy of Peptides. Learn More

Other selected research from the 'Oncology' category:


Renal Cancer Drug Pipeline Update
BioSeeker Group have identified 243 companies plus partners who are today developing 270 drugs targeting renal cancer in development. across 233 different targets. In addition, there are 3 suspended drugs and another 95 drugs where development has been ceased. Learn More


Hedgehog Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 163 companies plus partners who are today developing 203 Hedgehog pathway targeting drugs in 883 developmental projects in cancer across 133 different targets. In addition, there are 3 suspended drugs and another 90 drugs where development has been ceased. Learn More